<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1245">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144945</url>
  </required_header>
  <id_info>
    <org_study_id>VAP00016</org_study_id>
    <secondary_id>U1111-1253-2122</secondary_id>
    <nct_id>NCT05144945</nct_id>
  </id_info>
  <brief_title>Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea</brief_title>
  <official_title>A Phase III Randomized, Modified Double-blind, Active-controlled, Multi-center Study to Describe the Immunogenicity and Safety of the Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To describe the immune response induced by RIV4 and IIV4 in 18-49 and ≥ 50 years of age&#xD;
           participants by hemagglutination inhibition (HAI) measurement method&#xD;
&#xD;
        -  To describe the safety profile of all participants in RIV4 and IIV4 groups&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of each participant's participation will be approximately 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 25, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In each age group (18-49 and ≥ 50 years of age), participants will be randomized in a 1:1 ratio to each of the vaccines</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Modified double-blind: A designated unblinded administrator will administer the appropriate vaccine but will not be involved in the immunogenicity and safety assessments</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of influenza vaccine antibodies</measure>
    <time_frame>From Day 1 to Day 29</time_frame>
    <description>Antibody titers are expressed as GMTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratio (GMTR) of influenza vaccine antibodies before and after vaccination</measure>
    <time_frame>From Day 1 to Day 29</time_frame>
    <description>Individual antibody titer ratio 29 days after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving seroconversion</measure>
    <time_frame>From Day 1 to Day 29</time_frame>
    <description>Seroconversion for participants with a pre-vaccination titer lower than (&lt;) 10 [1/dil] at D1 and a post-vaccination titer ≥ 40 [1/dil] at D29, or a pre-vaccination titer ≥ 10 [1/dil] at D1 and a ≥ 4-fold increase in post-vaccination titer at D29</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with antibody titers greater than or equal to (≥) 40 [1/dil]</measure>
    <time_frame>From Day 1 to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with detectable antibody titers ≥ 10 [1/dil]</measure>
    <time_frame>From Day 1 to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with immediate adverse events (AEs)</measure>
    <time_frame>Within 30 minutes after vaccination</time_frame>
    <description>Immediate adverse events includes unsolicited systemic adverse events within 30 minutes after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants reporting solicited injection site reactions and systemic reactions</measure>
    <time_frame>Within 7 days after vaccination</time_frame>
    <description>Adverse reactions prelisted in the (electronic) case report book (CRB) Injection site reactions: pain, erythema, swelling Systemic reactions: fever, headache, malaise, myalgia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants reporting unsolicited AEs</measure>
    <time_frame>Within 28 days after vaccination</time_frame>
    <description>AEs other than solicited reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants reporting serious adverse events (SAEs)</measure>
    <time_frame>Within 6 months after vaccination</time_frame>
    <description>SAEs, including adverse event of special interest (AESIs)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Influenza (Healthy Volunteers)</condition>
  <arm_group>
    <arm_group_label>RIV4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIV4 single injection at Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIV4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IIV4, single injection at Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Recombinant Influenza Vaccine (RIV4)</intervention_name>
    <description>Solution for intramuscular injection</description>
    <arm_group_label>RIV4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent inactivated influenza vaccine (IIV4)</intervention_name>
    <description>Suspension for intramuscular injection</description>
    <arm_group_label>IIV4</arm_group_label>
    <other_name>Fluarix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 18 years on the day of inclusion&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all study procedures&#xD;
&#xD;
          -  Informed consent form has been signed and dated&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding and one of the following conditions applies:&#xD;
&#xD;
        Is of non-childbearing potential. To be considered of non-childbearing potential, a female&#xD;
        must be postmenopausal for at least 1 year, or surgically sterile OR Is of childbearing&#xD;
        potential and agrees to use an effective contraceptive method or abstinence from at least 4&#xD;
        weeks prior to the study intervention administration until at least 4 weeks after study&#xD;
        intervention administration.&#xD;
&#xD;
        A female participant of childbearing potential must have a negative highly sensitive&#xD;
        pregnancy test (urine) before the first dose of study intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  Participation at the time of study enrollment, or in the 6 months preceding the study&#xD;
             vaccination, or planned participation during the present study period in another&#xD;
             clinical study investigating involving an IMP (vaccine, drug), medical device, or&#xD;
             medical procedure or in any other type of medical research&#xD;
&#xD;
          -  Receipt of any vaccine in the 4 weeks (28 days) preceding the study vaccination or&#xD;
             planned receipt of any vaccine prior to Visit 2&#xD;
&#xD;
          -  Previous vaccination against influenza (in the preceding 6 months) with either the&#xD;
             study vaccine or another vaccine&#xD;
&#xD;
          -  Receipt of immune globulins, blood, or blood-derived products in the past 3 months&#xD;
&#xD;
          -  Known or suspected abnormal immune function: immunosuppression, suspected congenital&#xD;
             or acquired immunodeficiency based on medical history and physical examination, or&#xD;
             receipt of immunosuppressive therapy, such as anti-cancer chemotherapy, or radiation&#xD;
             therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy&#xD;
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)&#xD;
&#xD;
          -  Known systemic hypersensitivity to any of the vaccine components, or history of a&#xD;
             life-threatening reaction to the vaccines used in the study or to a vaccine containing&#xD;
             any of the same substances&#xD;
&#xD;
          -  Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on the&#xD;
             Investigator's judgment&#xD;
&#xD;
          -  Deprived of freedom by an administrative or court order, or in an emergency setting,&#xD;
             or hospitalized involuntarily&#xD;
&#xD;
          -  Current alcohol abuse or drug addiction that in the opinion of the Investigator might&#xD;
             interfere with the study conduct or completion&#xD;
&#xD;
          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it might&#xD;
             interfere with trial conduct or completion (Chronic illness may include, but is not&#xD;
             limited to, cardiac disorders, renal disorders, auto-immune disorders, diabetes,&#xD;
             psychiatric disorders, or chronic infection)&#xD;
&#xD;
          -  Moderate or severe acute illness/infection (according to Investigator judgment) on the&#xD;
             day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective&#xD;
             participant should not be included in the study until the condition has resolved or&#xD;
             the febrile event has subsided.&#xD;
&#xD;
          -  Personal or family history of Guillain-Barré syndrome (GBS)&#xD;
&#xD;
          -  Neoplastic disease or any hematologic malignancy (except localized skin or prostate&#xD;
             cancer that is stable at the time of vaccination in the absence of therapy and&#xD;
             participants who have a history of neoplastic disease and have been disease-free for ≥&#xD;
             5 years)&#xD;
&#xD;
          -  Identified as an Investigator or employee of the Investigator or study center with&#xD;
             direct involvement in the proposed study, or identified as an immediate family member&#xD;
             (ie, parent, spouse) of the Investigator or employee with direct involvement in the&#xD;
             proposed study&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a potential&#xD;
        participation in a clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

